trending Market Intelligence /marketintelligence/en/news-insights/trending/O5aRxkVe3F2C5FJGXgqOtg2 content esgSubNav
In This List

ESMO conference: X4, Pfizer drug combo prolongs lives of kidney cancer patients

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ESMO conference: X4, Pfizer drug combo prolongs lives of kidney cancer patients

X4 Pharmaceuticals Inc. said a combination of its experimental drug X4P-001 with Pfizer Inc.'s Inlyta helped patients with a type of kidney cancer live longer without their disease worsening during a mid-stage trial.

Cambridge, Mass.-based X4 was studying the drug combination in patients with advanced clear cell renal cell carcinoma, a cancer that develops in tiny tubules in the kidney's filtration system. Patients in the trial had received several previous treatments, with a majority having an intermediate or poor prognosis.

SNL Image

Patients receiving the combination of X4P-001, or mavorixafor, and Inlyta on average lived 7.4 months without the disease progressing or death, compared to 4.8 months historically seen in patients taking just Inlyta.

The European Commission and the U.S. Food and Drug Administration have granted orphan drug designation to mavorixafor as a treatment for warts and a number of other conditions.

The FDA approved a combination of Merck KGaA's Bavencio and Inlyta, also called axitinib, in May as an initial treatment of patients with advanced renal cell carcinoma.

X4 is a biopharmaceutical company focusing on the discovery, development and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer.

The European Society for Medical Oncology is holding its 2019 scientific meeting in Barcelona, where more than 3,900 study abstracts have been submitted for review by oncology professionals from around the world.